These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36358393)

  • 1. Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson's Disease Patients with Major Depression: An Open-Label Prospective Study.
    Santos García D; Alonso Losada MG; Cimas Hernando I; Cabo López I; Yáñez Baña R; Alonso Redondo R; Paz González JM; Cores Bartolomé C; Feal Painceiras MJ; Íñiguez Alvarado MC; Labandeira C; García Díaz I
    Brain Sci; 2022 Oct; 12(11):. PubMed ID: 36358393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.
    Santos García D; Fernández Pajarín G; Oropesa-Ruiz JM; Escamilla Sevilla F; Rahim López RRA; Muñoz Enríquez JG
    Brain Sci; 2022 Mar; 12(3):. PubMed ID: 35326339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study.
    Christensen MC; Schmidt S; Grande I
    J Psychopharmacol; 2022 May; 36(5):566-577. PubMed ID: 35499104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safinamide Improves Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.
    Santos García D; Labandeira Guerra C; Yáñez Baña R; Cimas Hernando MI; Cabo López I; Paz Gonález JM; Alonso Losada MG; González Palmás MJ; Martínez Miró C
    Brain Sci; 2021 Mar; 11(3):. PubMed ID: 33801565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study.
    McCue M; Sarkey S; Eramo A; François C; Parikh SV
    BMC Psychiatry; 2021 Dec; 21(1):622. PubMed ID: 34895181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
    Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
    Inoue T; Nishimura A; Sasai K; Kitagawa T
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
    Baldwin DS; Florea I; Jacobsen PL; Zhong W; Nomikos GG
    J Affect Disord; 2016 Dec; 206():140-150. PubMed ID: 27474960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Alam MY; Jacobsen PL; Chen Y; Serenko M; Mahableshwarkar AR
    Int Clin Psychopharmacol; 2014 Jan; 29(1):36-44. PubMed ID: 24169027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer's disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea.
    Cumbo E; Adair M; Åstrom DO; Christensen MC
    Front Aging Neurosci; 2022; 14():1037816. PubMed ID: 36698860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
    Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
    CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study.
    Jacobsen P; Zhong W; Xu R; Nomikos G
    J Affect Disord; 2020 Apr; 266():173-181. PubMed ID: 32056873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Effects of Vortioxetine on Cognitive Functions in Mild Alzheimer's Disease Patients with Depressive Symptoms: A 12 Month, Open-Label, Observational Study.
    Cumbo E; Cumbo S; Torregrossa S; Migliore D
    J Prev Alzheimers Dis; 2019; 6(3):192-197. PubMed ID: 31062834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zishen pingchan granules combined with pramipexole in the improvement of depressive symptoms in Parkinson's disease: a prospective, multicenter, randomized, double-blind, controlled clinical study.
    Ning H; Zhou H; Ren J; Zhou G; Yang N; Wang Z; Yuan C; Tian Z; Chen J; Shen L; Zheng H; Zhao Y; Wang H; Liu W; Liu Z
    J Transl Med; 2022 Aug; 20(1):357. PubMed ID: 35962349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression.
    Santos-García D; de Deus Fonticoba T; Suárez Castro E; Aneiros Díaz A; Cores Bartolomé C; Feal Panceiras MJ; Paz González JM; Valdés Aymerich L; García Moreno JM; Blázquez Estrada M; Jesús S; Mir P; Aguilar M; Planellas LL; García Caldentey J; Caballol N; Legarda I; Cabo López I; López Manzanares L; Ávila Rivera MA; Catalán MJ; López Díaz LM; Borrué C; Álvarez Sauco M; Vela L; Cubo E; Martínez Castrillo JC; Sánchez Alonso P; Alonso Losada MG; López Ariztegui N; Gastón I; Pascual-Sedano B; Seijo M; Ruíz Martínez J; Valero C; Kurtis M; González Ardura J; Prieto Jurczynska C; Martinez-Martin P;
    J Neurol Sci; 2020 Nov; 418():117109. PubMed ID: 32927370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Safinamide over Mood in Parkinson's Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR.
    Labandeira CM; Alonso Losada MG; Yáñez Baña R; Cimas Hernando MI; Cabo López I; Paz González JM; Gonzalez Palmás MJ; Martínez Miró C; Santos García D
    Adv Ther; 2021 Oct; 38(10):5398-5411. PubMed ID: 34523075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders.
    Findling RL; Robb AS; DelBello MP; Huss M; McNamara NK; Sarkis EH; Scheffer RE; Poulsen LH; Chen G; Lemming OM; Auby P
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):47-54. PubMed ID: 29035574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G; Gislum M; Filippov G; Montgomery S
    Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pingchan granule for depressive symptoms in parkinson's disease: A randomized, double-blind, placebo-controlled trial.
    Gu SC; Zhou J; Ye Q; Yuan CX
    J Integr Med; 2021 Mar; 19(2):120-128. PubMed ID: 33446472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.